BENJAMIN LLOYD: Open Payments
NPI 1013557941 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,596 in 89 payments from 19 companies in 2025. Trend: 2023 $59 · 2024 $284 · 2025 $1,596
Food & beverage: $1,596
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $337 |
| Grifols USA, LLC | 13 | $219 |
| Avadel CNS Pharmaceuticals, LLC | 14 | $196 |
| Insmed, Inc. | 12 | $171 |
| Verona Pharma, Inc. | 4 | $87 |
| Electromed, Inc. | 6 | $65 |
| GENZYME CORPORATION | 4 | $64 |
| Regeneron Healthcare Solutions, Inc. | 4 | $64 |
| Actelion Pharmaceuticals US, Inc. | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
Products named: FASENRA, Prolastin-C Liquid, LUMRYZ, Arikayce, DUPIXENT, Ohtuvayre, SMARTVEST, OPSYNVI.
Industry payments across NE — which companies pay providers there.
